| Abstrakt: |
Background: Four thousand neonates with Persisten Ductus Arteriosus every year in Indonesia. There are two treatment options to treat Persistent Ductus Arteriosus, they are surgery and pharmacological therapy. Ibuprofen and paracetamol can be used as pharmacological therapy for Persistent Ductus Arteriosus with minimal side effects. Objective: To analyze the prevalence and success factors in giving ibuprofen and paracetamol in neonates with persistent ductus arteriosus. Method: This research is an observational analytic research with cross-sectional method. The determination of the research sample uses a total sampling technique by taking all members of the population in accordance with the conditions from January, 2016 to March, 2020. Bivariate analysis was perform using the Spearman rank test with 95% confidence interval (a=0.05). Result: From 51 samples that met the inclusion criterias, it was found that the most criterias were male (66.67%), normal birth weight (60.78%), aterm (76.48%), moderate defect size before being administrated pharmacological therapy (47.06%), pharmacological therapy using paracetamol (88.24%), atrial septal defect in the cardiac comorbidities category (21.74%) and hyperbilirubinemia in the non-cardiac comorbidities category (13.04%). The majority of lumen defects in neonates were closed completely after being administrated pharmacological therapy (72.55%). Statistical test results of spearman rank showed that no significant relationship between birth weight and pharmacological therapy in RSUD Dr. Soetomo. There was a significant relationship between gestation and pharmacological therapy (p = 0.000; r = -0.495; r2 = 0.237, 95% CI). There was a significant relationship between the size of the ductus arteriosus defect before therapy and pharmacological therapy (p = 0.001; r = -0.435; r2 = 0.211, 95% CI). Conclusion: The success factors in administrating ibuprofen and paracetamol for neonates with persistent ductus arteriosus in RSUD dr. Soetomo from January 1, 2016 to March 3, 2020 were affected by gestation period and size of the ductus arteriosus defect prior to pharmacological therapy. [ABSTRACT FROM AUTHOR] |
